Received Jun 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 279C4 | — |
pediatric dose of Havrix was administered to a 33 year old female; pediatric dose of Havrix was administered to a 33 year old female; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult use of a child product in a 33-year-old female patient who received HAV (Havrix pediatric) (batch number 279C4, expiry date 20-SEP-2025) for prophylaxis. On 08-MAY-2025, the patient received Havrix pediatric. On 08-MAY-2025, an unknown time after receiving Havrix pediatric, the patient experienced adult use of a child product (Verbatim: pediatric dose of Havrix was administered to a 33 year old female) and underdose (Verbatim: pediatric dose of Havrix was administered to a 33 year old female). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 02-JUN-2025 The Vaccine Administration Facility is the same as Primary Reporter A medical assistant called in to report that a pediatric of Havrix was administered to a 33 year old female on May 8th 2025 which led to adult use of a child product and underdose.